바이오모아 (BioMoa) — ADC · Antibody

8428프로그램 40FDA 승인

0오늘 방문

1,453누적 방문

7303갱신 대기 S–CData Tier S/A/B차세대 1032HER2 breast 4683Antibody 2713CGT →Psoriasis →NSCLC 40FDA 승인

피드 Data Tier 차세대

최근 활동

RSS →

CGTBiologicstaleBeijing BiotechPhase 2

EB-PT-CAR-NK-S (EB-PT-CAR-NK-S)

Advanced or Metastatic Solid Tumors · Advanced or Metastatic Solid Tumors

#AdvancedorMetastaticSolidTumors#CGT#Phase2#세포유전치료#CAR-T+2

임상시험 1상태 RECRUITING

CGTBiologicstaleHangzhou Cancer HospitalPhase 1

NK Cell adaptive transfer (NK Cell adaptive transfer)

Advanced Cancer; ADCC · Advanced Cancer

#AdvancedCancer#CGT#Phase1#세포유전치료#CAR-T+3

임상시험 1상태 ACTIVE

CGTBiologicstaleThe Catholic University of KoreaPhase 2

Ex vivo-expanded NK cell enriched lymphocytes (ANKL, ANKL(Ex vivo-expanded NK cell enriched lymphocytes))

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#CGT#Phase2#세포유전치료#CAR-T+2

임상시험 1상태 ACTIVE

CGTBiologicstaleWashington University School of…Phase 2

Cytokine-induced memory-like NK cells (Cytokine-induced memory-like NK cells)

Refractory Acute Myeloid Leukemia; Relapsed Acute Myeloid Leukemia · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+4

임상시험 1상태 DISCONTINUED

CGTBiologicstaleBeijing BiotechPhase 2

EB-MF-CAR-NK-01 (EB-MF-CAR-NK-01)

Malignant Pleural Mesotheliomas · Malignant Pleural Mesotheliomas

#MalignantPleuralMesotheliomas#CGT#Phase2#세포유전치료#CAR-T+2

임상시험 1상태 RECRUITING

CGTBiologicstaleBangdong GongPhase 2

CAR-NK cell (CAR-NK cell)

Primary Sjogren's Syndrome; Lymphoma · Primary Sjogren's Syndrome

#PrimarySjogrensSyndrome#CGT#Phase2#세포유전치료#CAR-T+3

임상시험 1상태 RECRUITING

CGTBiologicstaleThe Affiliated Nanjing Drum Tow…Phase 2

NK cell perfusion group (NK cell perfusion group)

Abortion, Missed; Infertility Unexplained · Abortion, Missed

#AbortionMissed#CGT#Phase2#세포유전치료#CAR-T+5

임상시험 1상태 RECRUITING

CGTBiologicstaleThe Children's Hospital of Zhej…Phase 1

KN5601 (anti-CD19/BCMA CAR NK cells, anti-CD19/BCMA CAR NK cells (KN5601))

Autoimmune Diseases; Systemic Lupus Erthematosus · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 1상태 RECRUITING

CGTBiologicstaleXinqiao Hospital of ChongqingPhase 1

anti-CD33 CAR NK cells (anti-CD33 CAR NK cells)

Leukemia, Myeloid, Acute · CD33

#CD33#CGT#Phase1#세포유전치료#CAR-T+5

임상시험 1상태 ACTIVE

AntibodystaleXencor, Inc.Phase 2

Vudalimab + Carboplatin + Pemetrexed (Vudalimab + Carboplatin + Pemetrexed)

Nonsquamous Non-small Cell Lung Cancer · Nonsquamous Non-small Cell Lung Cancer

#NonsquamousNon-smallCellLungCanc#Antibody#Phase2#항체#면역항체+2

임상시험 1상태 DISCONTINUED

AntibodystaleMedivirPhase 2

pembrolizumab (Keytruda, MIV-818, MIV-818 (fostroxacitabine bralpamide) + pembrolizumab, fostroxacitabine bralpamide)

Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#항체#면역항체+3

임상시험 1상태 ACTIVE

CGTBiologicstaleBeijing BiotechPhase 2

DLL3/CD56 CAR-NK cells (EB-DART-NK01, EB-DART-NK01 (DLL3/CD56 CAR-NK cells))

Small Cell Lung Cancer (SCLC); Relapsed/Refractory SCLC · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+5

임상시험 1상태 RECRUITING

CGTBiologicstaleGuangzhou Ruixin Biotechnologic…Phase 1

iNK cells (iNK cells)

Acute Myeloid Leukemia (AML) · Acute Myeloid Leukemia (AML)

#AcuteMyeloidLeukemiaAML#CGT#Phase1#세포유전치료#CAR-T+2

효능 ORR 58.7%임상시험 1상태 RECRUITING

CGTBiologicstaleThe Affiliated Nanjing Drum Tow…Phase 1

autologous decidual-like NK cells (autologous decidual-like NK cells)

Abortion, Habitual; Infertility Unexplained · Abortion, Habitual

#AbortionHabitual#CGT#Phase1#세포유전치료#CAR-T+5

임상시험 1상태 RECRUITING

CGTBiologicstaleMonica ThakarPhase 2

Donor NK Cell Infusion (Donor NK Cell Infusion)

Ewing Sarcoma; Neuroblastoma · Ewing Sarcoma

#EwingSarcoma#CGT#Phase2#세포유전치료#CAR-T+3

임상시험 1상태 DISCONTINUED

CGTBiologicstaleThird Affiliated Hospital, Sun …Phase 1

Normal Dose NK cells ×4 times (Normal Dose NK cells ×4 times)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#CGT#Phase1#세포유전치료#CAR-T+2

임상시험 1상태 ACTIVE

CGTBiologicstaleThird Affiliated Hospital, Sun …Phase 1

Normal Dose NK cells ×8 times (Normal Dose NK cells ×8 times)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#CGT#Phase1#세포유전치료#CAR-T+2

임상시험 1상태 ACTIVE

CGTBiologicstaleNational University Hospital, S…Phase 1

Interleukin, NK cells (Interleukin, NK cells)

Metastatic Nasopharyngeal · Metastatic Nasopharyngeal

#MetastaticNasopharyngeal#CGT#Phase1#세포유전치료#CAR-T+2

임상시험 1상태 ACTIVE

AntibodystaleUNC Lineberger Comprehensive Ca…Phase 2

pembrolizumab (Keytruda, Neoadjuvant Pembrolizumab)

Breast Cancer; Triple Negative Breast Cancer (TNBC) · HER2

#HER2#Antibody#Phase2#항체#면역항체+4

임상시험 1상태 RECRUITING

AntibodystaleDana-Farber Cancer InstitutePhase 2

Pembroluzimab (Pembroluzimab)

HPV-positive Oropharyngeal Squamous Cell Carcinoma; Oropharyngeal Squamous Cell Carcinoma · HPV-positive Oropharyngeal Squamous Cell

#HPV-positiveOropharyngealSquamou#Antibody#Phase2#항체#면역항체+3

효능 ORR 0.0%임상시험 1상태 RECRUITING

AntibodystaleCentre Leon BerardPhase 2

atezolizumab (Tecentriq, 2 cycles of atezolizumab followed by surgery then post-operative radiotherapy)

Sarcoma,Soft Tissue · Sarcoma,Soft Tissue

#SarcomaSoftTissue#Antibody#Phase2#항체#면역항체+4

임상시험 1상태 RECRUITING

CGTBiologicstaleZhejiang Provincial People's Ho…Phase 2

NKG2D CAR-NK with PD-1 Antibody (NKG2D CAR-NK with PD-1 Antibody)

Anaplastic Throid Carcinoma · PD-1

#PD-1#CGT#Phase2#세포유전치료#CAR-T+3

임상시험 1상태 RECRUITING

CGTBiologicstaleChongqing Public Health Medical…Phase 2

NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells (NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells)

COVID-19 · COVID-19

#COVID-19#CGT#Phase2#세포유전치료#CAR-T+2

임상시험 1상태 ACTIVE

CGTBiologicstaleXiangyang No.1 People's HospitalPhase 2

autologous NK cell (autologous NK cell)

NK Cell; B-cell Lymphoma Recurrent · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+4

효능 ORR 0.667%임상시험 1상태 RECRUITING

CGTBiologicstaleChangzhou No.2 People's HospitalPhase 1

KN5501 (anti-CD19 CAR NK cells, anti-CD19 CAR NK cells (KN5501))

Thrombocytopenia Alloimmune · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+3

효능 ORR 0%임상시험 1상태 RECRUITING

115 / 142 페이지

← 이전 다음 →

전체 8,428개 프로그램 보기

갱신 기록 없음 · 14일 주기 · 방문 0 / 1,453

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

EB-PT-CAR-NK-S (EB-PT-CAR-NK-S)

NK Cell adaptive transfer (NK Cell adaptive transfer)

Ex vivo-expanded NK cell enriched lymphocytes (ANKL, ANKL(Ex vivo-expanded NK cell enriched lymphocytes))

Cytokine-induced memory-like NK cells (Cytokine-induced memory-like NK cells)

EB-MF-CAR-NK-01 (EB-MF-CAR-NK-01)

CAR-NK cell (CAR-NK cell)

NK cell perfusion group (NK cell perfusion group)

KN5601 (anti-CD19/BCMA CAR NK cells, anti-CD19/BCMA CAR NK cells (KN5601))

anti-CD33 CAR NK cells (anti-CD33 CAR NK cells)

Vudalimab + Carboplatin + Pemetrexed (Vudalimab + Carboplatin + Pemetrexed)

pembrolizumab (Keytruda, MIV-818, MIV-818 (fostroxacitabine bralpamide) + pembrolizumab, fostroxacitabine bralpamide)

DLL3/CD56 CAR-NK cells (EB-DART-NK01, EB-DART-NK01 (DLL3/CD56 CAR-NK cells))

iNK cells (iNK cells)

autologous decidual-like NK cells (autologous decidual-like NK cells)

Donor NK Cell Infusion (Donor NK Cell Infusion)

Normal Dose NK cells ×4 times (Normal Dose NK cells ×4 times)

Normal Dose NK cells ×8 times (Normal Dose NK cells ×8 times)

Interleukin, NK cells (Interleukin, NK cells)

pembrolizumab (Keytruda, Neoadjuvant Pembrolizumab)

Pembroluzimab (Pembroluzimab)

atezolizumab (Tecentriq, 2 cycles of atezolizumab followed by surgery then post-operative radiotherapy)

NKG2D CAR-NK with PD-1 Antibody (NKG2D CAR-NK with PD-1 Antibody)

NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells (NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells)

autologous NK cell (autologous NK cell)

KN5501 (anti-CD19 CAR NK cells, anti-CD19 CAR NK cells (KN5501))

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

EB-PT-CAR-NK-S (EB-PT-CAR-NK-S)

NK Cell adaptive transfer (NK Cell adaptive transfer)

Ex vivo-expanded NK cell enriched lymphocytes (ANKL, ANKL(Ex vivo-expanded NK cell enriched lymphocytes))

Cytokine-induced memory-like NK cells (Cytokine-induced memory-like NK cells)

EB-MF-CAR-NK-01 (EB-MF-CAR-NK-01)

CAR-NK cell (CAR-NK cell)

NK cell perfusion group (NK cell perfusion group)

KN5601 (anti-CD19/BCMA CAR NK cells, anti-CD19/BCMA CAR NK cells (KN5601))

anti-CD33 CAR NK cells (anti-CD33 CAR NK cells)

Vudalimab + Carboplatin + Pemetrexed (Vudalimab + Carboplatin + Pemetrexed)

pembrolizumab (Keytruda, MIV-818, MIV-818 (fostroxacitabine bralpamide) + pembrolizumab, fostroxacitabine bralpamide)

DLL3/CD56 CAR-NK cells (EB-DART-NK01, EB-DART-NK01 (DLL3/CD56 CAR-NK cells))

iNK cells (iNK cells)

autologous decidual-like NK cells (autologous decidual-like NK cells)

Donor NK Cell Infusion (Donor NK Cell Infusion)

Normal Dose NK cells ×4 times (Normal Dose NK cells ×4 times)

Normal Dose NK cells ×8 times (Normal Dose NK cells ×8 times)

Interleukin, NK cells (Interleukin, NK cells)

pembrolizumab (Keytruda, Neoadjuvant Pembrolizumab)

Pembroluzimab (Pembroluzimab)

atezolizumab (Tecentriq, 2 cycles of atezolizumab followed by surgery then post-operative radiotherapy)

NKG2D CAR-NK with PD-1 Antibody (NKG2D CAR-NK with PD-1 Antibody)

NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells (NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells)

autologous NK cell (autologous NK cell)

KN5501 (anti-CD19 CAR NK cells, anti-CD19 CAR NK cells (KN5501))

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

EB-PT-CAR-NK-S (EB-PT-CAR-NK-S)

NK Cell adaptive transfer (NK Cell adaptive transfer)

Ex vivo-expanded NK cell enriched lymphocytes (ANKL, ANKL(Ex vivo-expanded NK cell enriched lymphocytes))

Cytokine-induced memory-like NK cells (Cytokine-induced memory-like NK cells)

EB-MF-CAR-NK-01 (EB-MF-CAR-NK-01)

CAR-NK cell (CAR-NK cell)

NK cell perfusion group (NK cell perfusion group)

KN5601 (anti-CD19/BCMA CAR NK cells, anti-CD19/BCMA CAR NK cells (KN5601))

anti-CD33 CAR NK cells (anti-CD33 CAR NK cells)

Vudalimab + Carboplatin + Pemetrexed (Vudalimab + Carboplatin + Pemetrexed)

pembrolizumab (Keytruda, MIV-818, MIV-818 (fostroxacitabine bralpamide) + pembrolizumab, fostroxacitabine bralpamide)

DLL3/CD56 CAR-NK cells (EB-DART-NK01, EB-DART-NK01 (DLL3/CD56 CAR-NK cells))

iNK cells (iNK cells)

autologous decidual-like NK cells (autologous decidual-like NK cells)

Donor NK Cell Infusion (Donor NK Cell Infusion)

Normal Dose NK cells ×4 times (Normal Dose NK cells ×4 times)